NCT01026233 - Cardiac Safety Study of Brentuximab Vedotin (SGN-35) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2011

Conditions

Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin

Interventions

DRUG

brentuximab vedotin

1.8 mg/kg IV every 21 days

Trial Locations (9)

New York University Cancer Institute, New York

Fox Chase Cancer Center, Philadelphia

University of Miami Hospital and Clinics, Miller School of Medicine, Miami

University Hospital of Cologne, Cologne

Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood

Baylor University Medical Center, Dallas

City of Hope National Medical Center, Duarte

Stanford Cancer Center, Stanford

University of Alabama at Birmingham, Birmingham